Contracts License Agreements

More

  • Oct 15- Bristol-Myers Squibb Co said on Thursday it agreed to exclusively license and collaborate with Five Prime Therapeutics Inc to develop and commercialize Five Prime's antibody program in the treatment of cancer. Five Prime will receive $350 million upfront and potential development and regulatory milestone payments, totaling $1.74 billion, for the...